Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic Dermatitis
Public ClinicalTrials.gov record NCT05048056. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Multi-center, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of AK120 in Adult Subjects With Moderate-to-Severe Atopic Dermatitis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a phase 2, multi-center, randomized, placebo-controlled, double-blind, parallel-group, dose-ranging study, conducted in subjects with moderate-to-severe atopic dermatitis.
Study identification
- NCT ID
- NCT05048056
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 79 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 29, 2021
- Primary completion
- May 16, 2023
- Completion
- May 16, 2023
- Last update posted
- Feb 25, 2025
2021 – 2023
United States locations
- U.S. sites
- 16
- U.S. states
- 8
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| AkesoBio Investigative Site 2003 | Little Rock | Arkansas | 72204 | — |
| AkesoBio Investigative Site 2010 | Canoga Park | California | 91303 | — |
| AkesoBio Investigative Site 2021 | San Diego | California | 92119 | — |
| AkesoBio Investigative Site 2023 | San Diego | California | 92120 | — |
| AkesoBio Investigative Site 2017 | San Francisco | California | 94127 | — |
| AkesoBio Investigative Site 2020 | Sherman Oaks | California | 91043 | — |
| AkesoBio Investigative Site 2009 | Hialeah | Florida | 33016 | — |
| AkesoBio Investigative Site 2001 | Hollywood | Florida | 33021 | — |
| AkesoBio Investigative Site 2011 | Miami | Florida | 33155 | — |
| AkesoBio Investigative Site 2002 | Weston | Florida | 33331 | — |
| AkesoBio Investigative Site 2022 | Ridgeland | Mississippi | 39157 | — |
| AkesoBio Investigative Site 2015 | Las Vegas | Nevada | 89145 | — |
| AkesoBio Investigative Site 2013 | Spartanburg | South Carolina | 29303 | — |
| AkesoBio Investigative Site 2005 | Rapid City | South Dakota | 57702 | — |
| AkesoBio Investigative Site 2004 | Houston | Texas | 77065 | — |
| AkesoBio Investigative Site 2018 | Houston | Texas | 77074 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 8 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05048056, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 25, 2025 · Synced Sep 9, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05048056 live on ClinicalTrials.gov.